Moderna Boosts 2026 Sales Target on Strong Vaccine Demand

Moderna sees a brighter path ahead. The drugmaker expects faster sales growth by 2026 because patients want its newest shots.

Company leaders raised their 2026 revenue forecast on Friday. They now expect sales to jump 15% to 25%. Earlier targets called for gains of 10% or less.

The chief executive says newer vaccines lead this surge. These new treatments are finding steady footing in key medical markets.

For investors, this shift offers a clearer roadmap. Moderna is proving it can grow well beyond its original covid shots.

Source: CNBC